SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:1SXP • DE000A3ENQ51

15.61 EUR
+0.91 (+6.19%)
Last: Feb 11, 2026, 04:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 21 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • 1SXP had a positive operating cash flow in the past year.
  • Each year in the past 5 years 1SXP has been profitable.
  • Each year in the past 5 years 1SXP had a positive operating cash flow.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • 1SXP has a Return On Assets of 9.16%. This is amongst the best in the industry. 1SXP outperforms 85.71% of its industry peers.
  • 1SXP's Return On Equity of 16.42% is amongst the best of the industry. 1SXP outperforms 80.95% of its industry peers.
  • 1SXP has a better Return On Invested Capital (13.06%) than 85.71% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is above the industry average of 10.06%.
Industry RankSector Rank
ROA 9.16%
ROE 16.42%
ROIC 13.06%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • The Profit Margin of 1SXP (14.85%) is better than 76.19% of its industry peers.
  • In the last couple of years the Profit Margin of 1SXP has grown nicely.
  • With a decent Operating Margin value of 18.95%, 1SXP is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • The Gross Margin of 1SXP (33.71%) is worse than 71.43% of its industry peers.
  • In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
Industry RankSector Rank
OM 18.95%
PM (TTM) 14.85%
GM 33.71%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
  • Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
  • 1SXP has about the same amout of shares outstanding than it did 5 years ago.
  • 1SXP has a better debt/assets ratio than last year.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.43, 1SXP belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
  • A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.09, 1SXP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 2.43
Altman-Z N/A
ROIC/WACC1.37
WACC9.55%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.50. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP has a better Current ratio (1.50) than 61.90% of its industry peers.
  • A Quick Ratio of 1.12 indicates that 1SXP should not have too much problems paying its short term obligations.
  • 1SXP has a Quick ratio of 1.12. This is in the better half of the industry: 1SXP outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.12
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for 1SXP have decreased by -2.02% in the last year.
  • Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.78% on average per year.
  • The Revenue has been growing slightly by 3.04% in the past year.
  • Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%

3.2 Future

  • 1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.98% yearly.
  • 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • 1SXP is valuated correctly with a Price/Earnings ratio of 16.09.
  • Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 85.71% of the companies listed in the same industry.
  • 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 28.03, which is the current average of the S&P500 Index.
  • 1SXP is valuated correctly with a Price/Forward Earnings ratio of 15.63.
  • Based on the Price/Forward Earnings ratio, 1SXP is valued cheaper than 85.71% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, 1SXP is valued a bit cheaper.
Industry RankSector Rank
PE 16.09
Fwd PE 15.63
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaply inside the industry as 80.95% of the companies are valued more expensively.
  • 1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 66.86
EV/EBITDA 8.46
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)5.4
PEG (5Y)1.17
EPS Next 2Y8.11%
EPS Next 3Y9.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • 1SXP has a Yearly Dividend Yield of 1.28%.
  • In the last 3 months the price of 1SXP has falen by -22.63%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.44. 1SXP pays more dividend than 95.24% of the companies in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.80, 1SXP is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.28%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 1SXP pays out 16.45% of its income as dividend. This is a sustainable payout ratio.
DP16.45%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (2/11/2026, 4:21:40 PM)

15.61

+0.91 (+6.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-11
Earnings (Next)02-11
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.35B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target20.16 (29.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.28%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.65%
PT rev (3m)-32.75%
EPS NQ rev (1m)-19.18%
EPS NQ rev (3m)-30.72%
EPS NY rev (1m)-2.62%
EPS NY rev (3m)-14.62%
Revenue NQ rev (1m)-2.74%
Revenue NQ rev (3m)-8.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.73%
Valuation
Industry RankSector Rank
PE 16.09
Fwd PE 15.63
P/S 2.38
P/FCF 66.86
P/OCF 13.07
P/B 2.64
P/tB 2.73
EV/EBITDA 8.46
EPS(TTM)0.97
EY6.21%
EPS(NY)1
Fwd EY6.4%
FCF(TTM)0.23
FCFY1.5%
OCF(TTM)1.19
OCFY7.65%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)5.4
PEG (5Y)1.17
Graham Number11.37
Profitability
Industry RankSector Rank
ROA 9.16%
ROE 16.42%
ROCE 16.33%
ROIC 13.06%
ROICexc 13.46%
ROICexgc 13.83%
OM 18.95%
PM (TTM) 14.85%
GM 33.71%
FCFM 3.57%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 2.43
Debt/EBITDA 0.3
Cap/Depr 182.22%
Cap/Sales 14.68%
Interest Coverage 11.84
Cash Conversion 67.54%
Profit Quality 24.01%
Current Ratio 1.5
Quick Ratio 1.12
Altman-Z N/A
F-Score6
WACC9.55%
ROIC/WACC1.37
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.